Companies / Metagenomi Therapeutics, Inc.

Metagenomi Therapeutics, Inc.

Nasdaq: MGXCIK 1785279EMERYVILLE, CA

Financials · FY2025

Revenue$25.21M
Net income$-87.87M
Total debt
Cash$39.03M
Diluted EPS$-2.36
Shares outstanding37.8M

Ownership

37.8M shares outstanding · as of Aug 6, 2026
1.7%Insiders
Ownership
Insiders1.68%635,694
Institutions19.06%7,200,256
Public float79.26%29,941,155

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 5

View all →
Insider% of sharesShares
Irish JianCEOChief Executive Officer · Director
0.88%333,770
Wapnick PamelaChief Financial Officer
0.50%187,375
Wein MatthewSee Remarks
0.30%114,549

Institutional holders 57

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q4 2025
as of
Norges Bank
13F manager
ExitCommon Stock$-343.1K-252K
-100.00%
0
low
Q1 2026
as of
Renaissance Technologies LLC
13F manager
AddCommon Stock$213.7K+160K
+25.38%
787,900
2.09% of shares
low
Q4 2024
as of
Barclays PLC
13F manager
AddCommon Stock$122.0K+34K
+388.40%
42,481
0.11% of shares
low
Q1 2026
as of
Millennium Management LLC
13F manager
TrimCommon Stock$-87.2K-65K
-27.67%
170,104
0.45% of shares
low
Q1 2026
as of
Two Sigma Investments, LP
13F manager
AddCommon Stock$74.2K+55K
+12.55%
496,767
1.31% of shares
low
Q1 2026
as of
Geode Capital Management, LLC
13F manager
AddCommon Stock$70.1K+52K
+17.09%
358,200
0.95% of shares
low
Q1 2026
as of
Marshall Wace, LLP
13F manager
TrimCommon Stock$-69.2K-52K
-65.22%
27,521
0.07% of shares
low
Q2 2026
as of
Quadrature Capital Ltd
13F manager
ExitCommon Stock$-54.9K-34K
-100.00%
0
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
MGXCommon StockEquity59102M104BBG00Y5ZXS77